Seres Therapeutics Inc (MCRB) - Total Liabilities
Based on the latest financial reports, Seres Therapeutics Inc (MCRB) has total liabilities worth $91.12 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Seres Therapeutics Inc equity growth rate to track the company's year-over-year net asset growth rate.
Seres Therapeutics Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Seres Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Seres Therapeutics Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Seres Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Seres Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
LightInTheBox Holding Co Ltd ARD
NYSE:LITB
|
USA | $75.99 Million |
|
Live Verdure Ltd
AU:LV1
|
Australia | AU$1.95 Million |
|
Promateris SA
RO:PPL
|
Romania | RON99.60 Million |
|
Airmate Cayman International Co Ltd
TW:1626
|
Taiwan | NT$5.39 Billion |
|
Space Hellas SA
AT:SPACE
|
Greece | €158.35 Million |
|
DSR Corp
KO:155660
|
Korea | ₩151.69 Billion |
|
Inovio Pharmaceuticals Inc
NASDAQ:INO
|
USA | $77.11 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Seres Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Seres Therapeutics Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.77 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Seres Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Seres Therapeutics Inc (2012–2025)
The table below shows the annual total liabilities of Seres Therapeutics Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $93.97 Million | -25.43% |
| 2024-12-31 | $126.03 Million | -68.76% |
| 2023-12-31 | $403.46 Million | +19.37% |
| 2022-12-31 | $338.00 Million | +51.33% |
| 2021-12-31 | $223.35 Million | +32.80% |
| 2020-12-31 | $168.19 Million | -6.96% |
| 2019-12-31 | $180.76 Million | +7.27% |
| 2018-12-31 | $168.52 Million | +30.81% |
| 2017-12-31 | $128.82 Million | -7.99% |
| 2016-12-31 | $140.01 Million | +1116.89% |
| 2015-12-31 | $11.51 Million | -92.01% |
| 2014-12-31 | $144.07 Million | +9542.97% |
| 2013-12-31 | $1.49 Million | +739.33% |
| 2012-12-31 | $178.00K | -- |
About Seres Therapeutics Inc
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in pat… Read more